19 Nov 2025late filing notice▼ Bad
GB SCIENCES INC notified the SEC that its quarterly report would be filed late.
Announcements, explained
Each one in plain English, with the numbers worked through for a shareholder.
17 Oct 2025late filing notice▼ Bad
GB SCIENCES INC notified the SEC that its annual report would be filed late.
17 Oct 2025late filing notice▼ Bad
GB SCIENCES INC notified the SEC that its quarterly report would be filed late.
12 Feb 2025late filing notice▼ Bad
GB SCIENCES INC notified the SEC that its quarterly report would be filed late.
27 Nov 2024quarterly activities report▼ Bad
GB SCIENCES INC reported quarterly revenue of $0 and a net loss of $191 thousand for the period ended 2024-09-30.
27 Nov 2024quarterly activities report▼ Bad
GB SCIENCES INC reported quarterly revenue of $0 and a net loss of $191 thousand for the period ended 2024-09-30.
14 Nov 2024late filing notice▼ Bad
GB SCIENCES INC notified the SEC that its quarterly report would be filed late.
15 Oct 2024material agreement▲ GoodMajor
Effective September 26, 2024 the company gave EndoPure Life Sciences, LLC an exclusive license to its cannabinoid-based Parkinson's disease treatment for Brazil and South America. The company gets a 5% royalty on gross sales there, and EndoPure provides capital and expertise for first-in-human trials in the region. No upfront payment amount is stated, only 'other consideration'. Dr. Andrea Small-Howard now signs as CEO, and the address has moved to 205 W. Russell Road, Las Vegas.
14 Aug 2024late filing notice▼ Bad
GB SCIENCES INC notified the SEC that its quarterly report would be filed late.
1 July 2024late filing notice▼ Bad
GB SCIENCES INC notified the SEC that its annual report would be filed late.
12 Feb 2024quarterly activities report▼ Bad
GB SCIENCES INC reported quarterly revenue of $0 and a net loss of $187 thousand for the period ended 2023-12-31.
20 Nov 2023quarterly activities report▼ Bad
GB SCIENCES INC reported quarterly revenue of $0 and a net loss of $434 thousand for the period ended 2023-09-30.
14 Nov 2023late filing notice▼ Bad
GB SCIENCES INC notified the SEC that its quarterly report would be filed late.
10 Oct 2023securities registration● Neutral
GB SCIENCES INC filed the final prospectus for a registered offering.
14 Aug 2023quarterly activities report▼ Bad
GB SCIENCES INC reported quarterly revenue of $0 and a net loss of $273 thousand for the period ended 2023-06-30.
2 Aug 2023securities registration● Neutral
GB SCIENCES INC filed notice of an exempt private placement.
30 June 2023late filing notice▼ Bad
GB SCIENCES INC notified the SEC that its annual report would be filed late.
10 Mar 2023agm notice● Neutral
GB SCIENCES INC shareholders approved the routine matters put to a vote at the company's annual meeting (director elections, auditor ratification, and the executive-pay advisory vote).
3 Feb 2023quarterly activities report▼ Bad
GB SCIENCES INC reported quarterly revenue of $0 and a net loss of $449 thousand for the period ended 2022-12-31.
23 Jan 2023agm notice● Neutral
GB SCIENCES INC announced its upcoming annual shareholder meeting, covering the routine agenda (director elections, auditor ratification, executive-pay advisory vote).
19 Jan 2023agm notice● Neutral
GB SCIENCES INC shareholders approved the routine matters put to a vote at the company's annual meeting (director elections, auditor ratification, and the executive-pay advisory vote).
14 Dec 2022agm notice● Neutral
GB SCIENCES INC shareholders approved the routine matters put to a vote at the company's annual meeting (director elections, auditor ratification, and the executive-pay advisory vote).
10 Nov 2022securities registration● Neutral
GB SCIENCES INC filed the final prospectus for a registered offering.
9 Nov 2022quarterly activities report▼ Bad
GB SCIENCES INC reported quarterly revenue of $0 and a net loss of $313 thousand for the period ended 2022-09-30.
30 Aug 2022capital raising announcement▼ Bad
On August 25, 2022 the company granted options to seven people, including officers and directors, who will help get the company's shares listed on NASDAQ. The options vest only when the up-listing takes effect, cover 13% of fully diluted shares at that date, and have an exercise price of 80% of the share value then. If the listing happens, this would dilute existing shareholders.
11 Aug 2022quarterly activities report▼ Bad
GB SCIENCES INC reported quarterly revenue of $0 and a net loss of $498 thousand for the period ended 2022-06-30.
30 June 2022late filing notice▼ Bad
GB SCIENCES INC notified the SEC that its annual report would be filed late.
3 June 2022securities registration● Neutral
GB SCIENCES INC filed notice of an exempt private placement.
10 Mar 2022securities registration● Neutral
GB SCIENCES INC filed the final prospectus for a registered offering.
11 Feb 2022quarterly activities report● Neutral
GB SCIENCES INC reported quarterly revenue of $0 and net income of $4.3 million for the period ended 2021-12-31.